The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.
Ovation launches a GLP-1 dataset with WGS enabling biomaker discovery to advance precision medicine in metabolic diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback